References
- Fung MK, Eder AF, Spitalnik SL, Westhoff CM, Eds. Technical manual. 19th ed. Bethesda, MD: AABB Press, 2017.
- Beattie K, Crawford M, Mallory D, Mougey R. Inhibition of blood group antibodies by soluble antigens. In: Mallory D, Ed. Immunohematology methods procedures. Washington, DC: American Red Cross, 1993, 31:1.
- Judd WJ, Johnson ST, Storry JR. Judd’s methods in Immunohematology. 3rd ed. Bethesda, MD: AABB Press, 2008.
- Reid M, Lomas-Francis C, Olsson M. The blood group antigen factsbook. 3rd ed. San Diego, CA: Academic Press, 2012.
- Seltsam A, Grueger D, Blasczyk R, Flegel WA. Easy identification of antibodies to high-prevalence Scianna antigens and detection of admixed alloantibodies using soluble recombinant Scianna protein. Transfusion 2009;49:2090–6.
- Anliker M, von Zabern I, Höchsmann B, et al. A new blood group antigen is defined by anti-CD59, detected in a CD59-deficient patient. Transfusion 2014;54:1817–22.
- Seltsam A, Wagner F, Lambert M, et al. Recombinant blood group proteins facilitate the detection of alloantibodies to high-prevalence antigens and reveal underlying antibodies: results of an international study. Transfusion 2014;54:1823–30.
- Rojewski MT, Schrezenmeier H, Flegel WA. Tissue distribution of blood group membrane proteins beyond red cells: evidence from cDNA libraries. Transfus Apher Sci 2006, 35:71–82.
- Flegel WA, Henry SM. Can anti-A1 cause hemolysis? Transfusion 2018;58:3036–7.
- Morgan WTJ. The human ABO blood group substances. Experientia 1947;III:257–300.
- Witebsky E, Klendshoj NC. The isolation of the blood group specific B substance. J Exp Med 1940;72:663–7.
- Grubb R. Correlation between Lewis blood group and secretor character in man. Nature 1948;162:933.
- Moulds JM, Rowe KE. Neutralization of Knops system antibodies using soluble complement receptor 1. Transfusion 1996;36:517–20.
- Wong SW. CD38 Monoclonal antibody therapies for multiple myeloma. Clin Lymphoma Myeloma Leuk 2015;15:635–45.
- Flegel WA, Chen Q, Castilho L, et al. Molecular immunohaematology round table discussions at the AABB annual meeting, Orlando 2016. Blood Transfus 2018;16:447–56.
- Tong B, Wang M. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises. Future Oncol 2018;14:2179–88.
- Oostendorp M, Lammerts van Bueren JJ, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion 2015;55; 1555–62.
- Velliquette RW, Aeshlimann J, Kirkegaard J, Shakarian G, Lomas-Francis C, Westhoff CM. Monoclonal anti-CD47 interference in red cell and platelet testing. Transfusion 2019;59:730–7.
- Judd WJ. Inhibition tests with soluble blood group substances. In: Judd WJ, Ed. Methods in immunohematology. 2nd ed. Durham, NC: Montgomery Scientific Publications, 1994;240.
- Seltsam A, Blasczyk R. Recombinant blood group proteins in clinical practice: from puzzling to binary antibody testing. ISBT Sci Ser 2016;11(Suppl 1):243–9.
- Byrne KM, Sheldon SL, Flegel WA. Organization and management of an accredited specialist in blood bank (SBB) technology program. Transfusion 2010;50:1612–7.